Neurocognitive Disorder: Diagnostic Methods, Treatment Challenges and Future Directions
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 1705
Special Issue Editor
Interests: Alzheimer’s disease; clinical neurophysiology; mild cognitive impairment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) is a neurodegenerative disease with a rising incidence among elderly people. It was first described in 1906 by a clinical psychiatrist and neuroanatomist named Alois Alzheimer. AD is the most common form of dementia and is characterized by progressive memory impairment. The worldwide prevalence of persons with dementia was 35.5 million in 2010, with the number of patients with dementia almost doubling every 20 years, being expected to reach 65.7 million in 2030 and 115.4 million in 2050. The early identification and treatment of patients with dementia should therefore be a public health priority.
In the DSM-5, the terms mild cognitive impairment and dementia were replaced by the terms mild neurocognitive disorder (NCD) and major NCD.
In this Special Issue, we welcome contributions in the form of original research, review articles on the study of diagnostic and prognostic biomarkers of NCD (neurophysiological, genetic and neuroimaging), as well as articles examining novel methods and future directions for NCD progression, diagnosis and treatment.
Dr. Vasileios Papaliagkas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurocognitive disorders
- Alzheimer’s disease
- clinical neurophysiology
- neuroimaging
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.